Lucis
-85%
est. 2Y upside i
Function Health for Europe
Rank
#510
Sector
Healthtech
Est. Liquidity
~5Y
Data Quality
Data: MediumLucis presents a compelling opportunity in the nascent European preventive health market, backed by strong investors and an innovative AI-driven approach.
Last updated: February 23, 2026
Lucis successfully navigates regulatory hurdles, rapidly expands across Europe, and achieves significant market adoption, leading to a high-multiple acquisition or successful later-stage funding round.
Lucis continues to grow steadily in key European markets, secures a strong Series A/B round, and establishes a solid, albeit not dominant, market position.
Regulatory challenges significantly impede expansion, competition intensifies, or the company fails to secure sufficient follow-on funding, leading to a down round or unfavorable exit for common shareholders.
Preference Stack Risk
highInvestors hold $9M in liquidation preferences. In an exit at the current estimated valuation of $35M, common shareholders would receive proceeds only after the $9M is returned to preferred shareholders, leaving $26M for common. If the exit is at or below $9M, common shareholders would receive nothing.
Dilution Risk
highAs a seed-stage company, Lucis will require multiple future funding rounds (Series A, B, C, etc.) to scale, which will significantly dilute the ownership percentage of early employees holding common stock or options.
Secondary Liquidity
noneGiven Lucis's early stage and small size, there is currently no active secondary market for employee equity, nor are tender offers likely in the near future.
Community
Valuation Sentiment
Our model estimates -85% upside. What do you think?
Anonymous. Do not share material non-public information.
Community Discussion
Comments are reviewed before they appear publicly.
Loading comments...
Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.